Skip to main content
Erschienen in: Reactions Weekly 1/2022

01.10.2022 | Case report

Antineoplastics

Treatment refractory, pulmonary toxicity and dyspnoea : 5 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Eaton A, et al. Tumor Genomic Profiling and Ex Vivo Drug Sensitivity Testing for Pediatric Leukemia and Lymphoma Patients. Journal of Pediatric Pharmacology and Therapeutics 27: 123-131, No. 2, 2022. Available from: URL: http://www.jppt.org/?code=ppag-site Eaton A, et al. Tumor Genomic Profiling and Ex Vivo Drug Sensitivity Testing for Pediatric Leukemia and Lymphoma Patients. Journal of Pediatric Pharmacology and Therapeutics 27: 123-131, No. 2, 2022. Available from: URL: http://​www.​jppt.​org/​?​code=​ppag-site
Metadaten
Titel
Antineoplastics
Treatment refractory, pulmonary toxicity and dyspnoea : 5 case reports
Publikationsdatum
01.10.2022
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2022
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-022-25320-z

Weitere Artikel der Ausgabe 1/2022

Reactions Weekly 1/2022 Zur Ausgabe

Case report

Covid-19-vaccine

Case report

Multiple drugs

Case report

Multiple drugs